Experimental combo targets Hard-to-Treat lymphoma

NCT ID NCT05896163

Terminated Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested two experimental drugs, maplirpacept and glofitamab, given after a single dose of obinutuzumab, in adults with diffuse large B-cell lymphoma (DLBCL) that had returned or not responded to prior treatments. Participants had already tried at least two standard therapies and could not or would not have a stem cell transplant. The goal was to find a safe and effective dose of the combination. However, the trial was terminated early, so full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: maplirpacept (PF-07901801) combined with glofitamab and obinutuzumab
What this could lead to: If it works, this could offer a new treatment option for people with DLBCL who have run out of standard therapies and cannot have a stem cell transplant.
What could go wrong: This trial was terminated early, so results may be limited. It is also an early-phase study (Phase 1b/2) with a small number of participants, so safety and effectiveness are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma lymphoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE LARGE B-CELL LYMPHOMA

Contacts and locations

Locations

Barnes-Jewish Hospital Parkview Tower

St Louis, Missouri, 63110, United States
Gazi University I lcalth Research and Annlica1ion Cenlcr Gazi Hospilal

Ankara, 06560, Turkey (Türkiye)
National Hospital Organization Kyushu Cancer Center

Fukuoka, 811-1395, Japan
Rambam Health Care Campus

Haifa, Northern District, 3109601, Israel
Sheba Medical Center

Ramat Gan, Central District, 5262100, Israel
Shizuoka Cancer Center

Nagaizumi-cho, Shizuoka, 411-8777, Japan
Siteman Cancer Center

St Louis, Missouri, 63108, United States
Sourasky Medical Center

Tel Aviv, TELL ABĪB, 6423906, Israel
University of Kansas Hospital Cambridge North Tower A

Kansas City, Kansas, 66160, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.